Metabolic syndrome and HPA axis biomarkers for major depressive disorder
Materials and methods for using combinations of metabolic syndrome and HPA axis biomarkers for monitoring major depressive disorder.
1. A process for diagnosing a human subject as having a depression disorder, comprising:
(a) performing an immunological assay to measure the level of each of EGF, resistin, and cortisol in a blood sample from the subject;
(b) comparing the measured levels of EGF, resistin, and cortisol with control levels of EGF, resistin, and cortisol, respectively, in blood samples; and
(c) diagnosing the subject as having said depression disorder when said measured levels of EGF, resistin, and cortisol are higher than said control levels.
2. The process of claim 1 , wherein said depression disorder is major depressive disorder.
3. The process of claim 1 , wherein said sample is a serum sample.
4. The process of claim 1 , wherein said sample is a plasma sample.
5. The process of claim 1 , wherein the control levels are levels of EGF, resistin, and cortisol in normal human subjects who do not have depression.